Skip to content

DS-1971a Phase 2 study

A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of DS-1971a in patients with pain caused by radiculopathy due to lumbar spinal stenosis

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080223138
Enrollment
180
Registered
2016-03-09
Start date
2016-03-09
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain caused by radiculopathy due to lumbar spinal stenosis

Interventions

investigational material(s) Generic name etc : DS-1971a INN of investigational material : Therapeutic category code : 114 Antipyretics, analgesics and anti-inflammatory agents Dosage and Administrati

Sponsors

DAIICHI SANKYO CO., LTD.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: -Subjects who are able to understand the study procedures, complete the electronic patient diary and electronic patient questionnaire, and appropriately answer the physician's questions. -Subjects who have lower limb pain caused by radiculopathy that has been persisting for at least 3 months before the start day of the screening period and that can be explained by lumbar spinal stenosis found by magnetic resonance imaging (MRI).

Exclusion criteria

Exclusion criteria: -Subjects who have undergone any lumbar surgery or require any lumbar surgery during the study period. -Subjects who have any disease that may affect the evaluation of pain of lower limbs (ASO, rheumatoid arthritis, diabetic peripheral neuropathy, etc.). -Subjects who have undergone any brain or spinal cord surgery or require any brain or spinal cord surgery during the study period -Subjects who have central neuropathic pain

Design outcomes

Primary

MeasureTime frame
Average daily pain score To compare the change from baseline in the weekly average daily pain score at end of treatment of DS-1971a to that for placebo.

Secondary

MeasureTime frame
HADS , SF-36 To compare the change from baseline in the HADS and SF-36 at end of treatment of DS-1971a to that for placebo.

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026